| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 07/24/2002 | EP1224305A2 Self-cleaving rna sequences and their use for the control of protein synthesis |
| 07/24/2002 | EP1224281A1 37 human secreted proteins |
| 07/24/2002 | EP1224280A2 Design of high affinity rnase h recruiting oligonucleotide |
| 07/24/2002 | EP1224274A1 Tumor necrosis factor related receptor, tr6 |
| 07/24/2002 | EP1224266A2 Lysosomal targeting pathway enzymes |
| 07/24/2002 | EP1224222A2 Chemokine receptor |
| 07/24/2002 | EP1224220A2 Epo primary response gene 1, eprg1 |
| 07/24/2002 | EP1224208A1 Human inwardly rectifying potassium channel subunit |
| 07/24/2002 | EP1224207A1 5-hydroxysapogenin derivatives with anti-dementia activity |
| 07/24/2002 | EP1224205A1 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia |
| 07/24/2002 | EP1224201A1 32 human secreted proteins |
| 07/24/2002 | EP1224195A1 C-aryl glucoside sglt2 inhibitors |
| 07/24/2002 | EP1224194A1 Hygromycin a prodrugs |
| 07/24/2002 | EP1224187A2 Certain alkylene diamine-substituted heterocycles |
| 07/24/2002 | EP1224183A2 Heterocyclic sodium/proton exchange inhibitors and method |
| 07/24/2002 | EP1224182A1 N-substituted 1-(lactone) isoquinolones for treating nervous disorders |
| 07/24/2002 | EP1224180A2 Substituted azoles |
| 07/24/2002 | EP1224179A2 Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 07/24/2002 | EP1224177A1 Process for preparing oxazolines from tetrahydrofurans |
| 07/24/2002 | EP1224175A2 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
| 07/24/2002 | EP1224174A2 Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
| 07/24/2002 | EP1224173A1 Pyrazole derivatives as cannabinoid receptor antagonists |
| 07/24/2002 | EP1224171A1 Beta disubstituted metalloprotease inhibitors |
| 07/24/2002 | EP1224166A1 Method of producing n-(4,5-bis-methanesulfonyl-2-methyl-benzoyl)-guanidine, the hydrochloride thereof |
| 07/24/2002 | EP1224163A1 Use of carbonylamino derivatives against cns disorders |
| 07/24/2002 | EP1224155A2 Novel bicyclic cannabinoid agonists for the cannabinoid receptor |
| 07/24/2002 | EP1223988A1 Antisense modulation of tumor necrosis factor alpha converting enzyme (tace) expression |
| 07/24/2002 | EP1223984A2 Compounds that associate on the intermolecular level and aggregate bodies that contain them |
| 07/24/2002 | EP1223974A2 Medicament in order to induce tolerance |
| 07/24/2002 | EP1223970A1 Short segments of dap-kinase |
| 07/24/2002 | EP1223969A2 Combined use of a plasminogen activator and il-2 inhibitors for neuroprotection |
| 07/24/2002 | EP1223966A2 Use of gdnf for treating corneal defects |
| 07/24/2002 | EP1223961A1 Trail: an inhibitor of autoimmune inflammation and cell cycle progression |
| 07/24/2002 | EP1223959A2 Inhbition of cell motility and angiogenesis by inhibitors of the grb2 sh2-domain |
| 07/24/2002 | EP1223956A1 Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation |
| 07/24/2002 | EP1223955A1 Fibrin sealants providing less inflammatory response and methods using same |
| 07/24/2002 | EP1223945A1 Compositions comprising oxophosphonate-based metalloproteinase inhibitors |
| 07/24/2002 | EP1223944A1 Thrombopoietin mimetics |
| 07/24/2002 | EP1223943A2 Therapeutic use of an inhibitor or an antagonist of an abc protein in bone |
| 07/24/2002 | EP1223936A1 Oral formulations for anti-tumor compounds |
| 07/24/2002 | EP1223933A2 5-membered heterocycle derivatives, production thereof and use thereof as medicaments |
| 07/24/2002 | EP1223932A1 Compounds and methods |
| 07/24/2002 | EP1223930A1 Treatment of dyskinesia |
| 07/24/2002 | EP1223929A1 Cannabimimetic indole derivatives |
| 07/24/2002 | EP1223925A2 Use of a fatty acid derivative for the treatment of external secretion disorders |
| 07/24/2002 | EP1223923A1 Method for protecting normal cells from cytotoxicity of chemotherapeutic agents |
| 07/24/2002 | EP1223918A1 Pharmaceutical compositions comprising a hmg coa reductase inhibitor |
| 07/24/2002 | EP1223916A2 Neutral-cationic lipid for nucleic acid and drug delivery |
| 07/24/2002 | EP1223913A2 Use of aromatic polycyclic compounds as activators of ppars-type receptors in a cosmetic or pharmaceutical composition |
| 07/24/2002 | EP1119367A4 Method of using fetuin to induce apoptosis in cancer cells |
| 07/24/2002 | EP1102743B1 Amide derivatives which are useful as cytokine inhibitors |
| 07/24/2002 | EP0983268B1 Amidine derivatives as inhibitors of nitric oxide synthase |
| 07/24/2002 | EP0966473B1 Thiazolobenzoheterocycles, preparation and medicines containing same |
| 07/24/2002 | EP0922034B1 Tetrahydroquinoline derivatives as eaa antagonists |
| 07/24/2002 | EP0904110B1 Nitric oxide donors capable of reducing toxicity from drugs |
| 07/24/2002 | EP0900218B1 Heterocyclic compounds |
| 07/24/2002 | EP0885230B1 Camptothecin derivatives and the use thereof as antitumor agents |
| 07/24/2002 | EP0869778B1 Improved perfluorocarbons for biological gas exchange and method |
| 07/24/2002 | EP0836485B1 Cascade polymer complexes |
| 07/24/2002 | EP0835263B9 Somatostatin peptides |
| 07/24/2002 | EP0739210B1 Compositions for local delivery of cytostatic agents |
| 07/24/2002 | EP0699192B1 Substituted oxazolyl compounds for the treatment of inflammation |
| 07/24/2002 | EP0684945B1 Pyrazole- or isoxazole-substituted alkyl amide acat inhibitors |
| 07/24/2002 | CN1360633A Fucosyl transferase gene |
| 07/24/2002 | CN1360594A Attenuated microorganisms for treatment of infection |
| 07/24/2002 | CN1360592A Streptogramin derivs., production thereof and composition contg. same |
| 07/24/2002 | CN1360583A Novel compounds, their use and preparation |
| 07/24/2002 | CN1360582A Quinazoline derivs. |
| 07/24/2002 | CN1360581A Benzoylpyridazines |
| 07/24/2002 | CN1360577A Hydroxamic acid derivs. as matrix metalloprotease inhibitors |
| 07/24/2002 | CN1360570A Phenyl sulfamate derivs. |
| 07/24/2002 | CN1360507A Conjugates and method for production thereof, and their use for transporting molecules via biological membranes |
| 07/24/2002 | CN1360496A Dry powder compositions |
| 07/24/2002 | CN1360494A Delivery system for oral care compositions comprising organosiloxane resins using removable backing strip |
| 07/24/2002 | CN1360493A Compositions comprising organosiloxane resins for delivering oral care substances |
| 07/24/2002 | CN1360492A Compositions comprising organosiloxane resins for delivering oral care substances |
| 07/24/2002 | CN1359900A Metal protease inhibitor, preparing process thereof and pharmaceutical composition contg. same |
| 07/24/2002 | CN1359686A Zymolite of blue scad capable of improving function of brain cells and its preparing process |
| 07/24/2002 | CN1088067C Separating method for sesanins |
| 07/24/2002 | CN1088064C Naphthoxazines derivs., process for their preparation and pharmaceutical compositions contg. them |
| 07/24/2002 | CN1088062C Certain 4-aminomethy-2-substd. imidazole derivs. and 2-aminomethyl-4-substd. imidazole derivs. new classes of dopamine receptor subtype specific ligands |
| 07/24/2002 | CN1087940C Brain protein hydrolysate |
| 07/24/2002 | CN1087937C Medicine of inhibiting Alzheimer's disease |
| 07/24/2002 | CN1087936C Use of thiadiazole and oxadiazole derivs. in preparing antipsychotic medicine |
| 07/24/2002 | CN1087935C Medicaments |
| 07/24/2002 | CN1087913C Silkworm chrysalis contg. compound amino acid oral liquid and preparing process thereof |
| 07/23/2002 | US6423870 Tricyclic compounds, preparation method and pharmaceutical compositions containing same |
| 07/23/2002 | US6423855 Prevention lysis; oxidation resistance |
| 07/23/2002 | US6423840 Forming n-acylamino compound |
| 07/23/2002 | US6423754 Method for treating hypercholesterolemia with polyallylamine polymers |
| 07/23/2002 | US6423753 Controlling angiogenesis |
| 07/23/2002 | US6423750 Systems for delivering anti-infective compositions to treat disordered tissue such as cold sores |
| 07/23/2002 | US6423747 Cosmetic and dermatological preparations with flavonoids |
| 07/23/2002 | US6423744 Administering an amount of a leukotriene b4 (ltb4) antagonist, preferably a ltb4 receptor antagonistic, to a patient exhibiting adverse drug effect due to exogenous interleukin-2, to decrease the adverse effects |
| 07/23/2002 | US6423737 Benzamidoxime prodrugs as antipneumocystic agents |
| 07/23/2002 | US6423729 Therapeutic or prophylactic agent for glomerulopathy |
| 07/23/2002 | US6423728 Heterocyclic thioamide derivatives |
| 07/23/2002 | US6423725 Analgesics |
| 07/23/2002 | US6423722 Antiinflammatory agents |
| 07/23/2002 | US6423720 Pyrimidine compounds and methods for making and using the same |